The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.

Drug Des Devel Ther · 2021 · PMC8232377 · PMID 34188449

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

23 A post-hoc analysis was conducted on patients who had asymptomatic and stable CNS disease at baseline (16.3% of total, 51 and 50 patients in the neratinib and lapatinib arm, respectively), confirming a positive trend in terms of PFS in favor of neratinib (7.8 months vs 5.5 months).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.